Esketamine-containing opioid-reduced PCA versus sufentanil PCA after laparoscopic sleeve gastrectomy: a randomized controlled trial

Postoperative pain management following bariatric surgery remains challenging, and conventional opioid-based analgesic regimens are associated with a range of adverse effects. We therefore evaluated whether an esketamine-containing reduced-opioid PCA regimen could improve analgesic efficacy during the initial 72 h after laparoscopic sleeve gastrectomy. In this single-center randomized controlled trial, 119 patients were randomly assigned 1:1 to either the esketamine group (EG) or the sufentanil group (SG), with block sizes of 2 or 4 and stratification by BMI. One patient in the SG was excluded after randomization because the planned laparoscopic sleeve gastrectomy was not performed, leaving 118 patients (EG 59, SG 59) in the modified intention-to-treat analysis. Group-based patient-controlled analgesia (PCA) was administered: EG received esketamine 1 mg/kg plus sufentanil 1 µg/kg, and sufentanil 2.5 µg/kg was used in SG. The primary outcome was postoperative pain intensity over 72 h assessed by the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption, postoperative nausea and vomiting (PONV), sleep quality, recovery indicators, and adverse events. Compared with the sufentanil group (SG), the esketamine group (EG) exhibited significantly lower dynamic pain scores over the 72-hour period (group effect: ATS = 12.59, df = 1.00, P < 0.001), whereas no significant overall group effect was observed for resting pain (ATS = 1.97, df = 1.00, P = 0.160). Regarding secondary outcomes, the EG was associated with lower postoperative sufentanil exposure and better sleep quality ( P < 0.001). Safety profiles were comparable between groups, except for a higher incidence of diaphoresis in the EG (23.7% vs. 5.1%; OR = 5.807; 95% CI, 1.571–21.464; P = 0.004). An esketamine–sufentanil, reduced-opioid PCA regimen, compared with a sufentanil PCA regimen, provided effective postoperative pain control after laparoscopic sleeve gastrectomy and was associated with lower early PONV. This prospective, randomized, double-blind clinical trial was registered with the Chinese Clinical Trial Registry on April 27, 2025 (ChiCTR2500101603).

Authors

Institutions

Publication Details

Journal
BMC Anesthesiology
Published
2026-11-18
DOI
https://doi.org/10.1186/s12871-026-04412-8
Primary Topic
Anesthesia and Pain Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Esketamine-containing opioid-reduced PCA versus sufentanil PCA after laparoscopic sleeve gastrectomy: a randomized controlled trial

Kai-Rui Shi, Huayu Shen, Chun Yang, Xiao-hai Jiang et al.
4 links
BMC Anesthesiology
Anesthesia and Pain Management
article

Esketamine-containing opioid-reduced PCA versus sufentanil PCA after laparoscopic sleeve gastrectomy: a randomized controlled trial

Kai-Rui Shi, Huayu Shen, Chun Yang, Xiao-hai Jiang, Ke Liu, Lin Jiang, Bing-yuan Zhang, Min Zhao
article en

Abstract

Postoperative pain management following bariatric surgery remains challenging, and conventional opioid-based analgesic regimens are associated with a range of adverse effects. We therefore evaluated whether an esketamine-containing reduced-opioid PCA regimen could improve analgesic efficacy during the initial 72 h after laparoscopic sleeve gastrectomy. In this single-center randomized controlled trial, 119 patients were randomly assigned 1:1 to either the esketamine group (EG) or the sufentanil group (SG), with block sizes of 2 or 4 and stratification by BMI. One patient in the SG was excluded after randomization because the planned laparoscopic sleeve gastrectomy was not performed, leaving 118 patients (EG 59, SG 59) in the modified intention-to-treat analysis. Group-based patient-controlled analgesia (PCA) was administered: EG received esketamine 1 mg/kg plus sufentanil 1 µg/kg, and sufentanil 2.5 µg/kg was used in SG. The primary outcome was postoperative pain intensity over 72 h assessed by the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption, postoperative nausea and vomiting (PONV), sleep quality, recovery indicators, and adverse events. Compared with the sufentanil group (SG), the esketamine group (EG) exhibited significantly lower dynamic pain scores over the 72-hour period (group effect: ATS = 12.59, df = 1.00, P < 0.001), whereas no significant overall group effect was observed for resting pain (ATS = 1.97, df = 1.00, P = 0.160). Regarding secondary outcomes, the EG was associated with lower postoperative sufentanil exposure and better sleep quality ( P < 0.001). Safety profiles were comparable between groups, except for a higher incidence of diaphoresis in the EG (23.7% vs. 5.1%; OR = 5.807; 95% CI, 1.571–21.464; P = 0.004). An esketamine–sufentanil, reduced-opioid PCA regimen, compared with a sufentanil PCA regimen, provided effective postoperative pain control after laparoscopic sleeve gastrectomy and was associated with lower early PONV. This prospective, randomized, double-blind clinical trial was registered with the Chinese Clinical Trial Registry on April 27, 2025 (ChiCTR2500101603).

BMC Anesthesiology
Nantong University (CN), The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN), Nanjing Medical University (CN)
Nanjing Medical University
Good health and well-being
Anesthesia and Pain Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon